Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

GlycoMimetics stock

GLYC
US38000Q1022
A1W8HZ

Price

0.17
Today +/-
-0.00
Today %
-1.91 %
P

GlycoMimetics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the GlycoMimetics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the GlycoMimetics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the GlycoMimetics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze GlycoMimetics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

GlycoMimetics Stock Price History

DateGlycoMimetics Price
10/1/20240.17 undefined
9/30/20240.17 undefined
9/27/20240.17 undefined
9/26/20240.17 undefined
9/25/20240.16 undefined
9/24/20240.16 undefined
9/23/20240.16 undefined
9/20/20240.16 undefined
9/19/20240.17 undefined
9/18/20240.16 undefined
9/17/20240.17 undefined
9/16/20240.16 undefined
9/13/20240.17 undefined
9/12/20240.16 undefined
9/11/20240.16 undefined
9/10/20240.16 undefined
9/9/20240.16 undefined
9/6/20240.16 undefined
9/5/20240.16 undefined
9/4/20240.16 undefined
9/3/20240.17 undefined

GlycoMimetics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into GlycoMimetics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by GlycoMimetics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects GlycoMimetics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of GlycoMimetics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into GlycoMimetics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing GlycoMimetics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on GlycoMimetics’s growth potential.

GlycoMimetics Revenue, EBIT and net profit per share

DateGlycoMimetics RevenueGlycoMimetics EBITGlycoMimetics Net Income
2029e77.16 M undefined0 undefined36.17 M undefined
2028e32.57 M undefined-58.15 M undefined-9.21 M undefined
2027e6.52 M undefined-72.29 M undefined-44.72 M undefined
2026e1.29 M undefined-44.74 M undefined-33.54 M undefined
2025e3.64 M undefined-39.4 M undefined-28.61 M undefined
2024e0 undefined-40.85 M undefined-39.96 M undefined
202310,000 undefined-39.28 M undefined-36.9 M undefined
202280,000 undefined-47.4 M undefined-46.69 M undefined
20211.16 M undefined-63.45 M undefined-63.43 M undefined
202010.16 M undefined-51.51 M undefined-51.03 M undefined
20190 undefined-61.39 M undefined-57.89 M undefined
20180 undefined-51.5 M undefined-48.27 M undefined
20170 undefined-33.93 M undefined-33.28 M undefined
201620,000 undefined-31.91 M undefined-31.81 M undefined
201520.07 M undefined-12.78 M undefined-12.77 M undefined
201415.03 M undefined-11.14 M undefined-11.12 M undefined
20133.99 M undefined-10.61 M undefined-10.61 M undefined
201215.26 M undefined3.64 M undefined3.66 M undefined
20113.81 M undefined-6.08 M undefined-6.11 M undefined

GlycoMimetics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
3153152000001010003163277
-400.00-80.00400.0033.33------90.00-----66.67500.00433.33140.63
-------------------
0000000000000000000
-63-10-11-12-31-33-51-61-51-63-47-39-40-39-44-72-580
-200.0020.00-333.33-73.33-60.00-----510.00-6,300.00----1,300.00-4,400.00-1,200.00-181.25-
-63-10-11-12-31-33-48-57-51-63-46-36-39-28-33-44-936
--150.00-433.3310.009.09158.336.4545.4518.75-10.5323.53-26.98-21.748.33-28.2117.8633.33-79.55-500.00
1.21.21.218.4519.0121.2629.441.0443.2545.7251.4552.5363.34000000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The GlycoMimetics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the GlycoMimetics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2011201220132014201520162017201820192020202120222023
                         
28.217.42.355.246.840.1123.9209.9158.213790.347.941.79
0000000000000
0000000000000
0000000000000
0.20.62.60.90.40.23.21.94.11.20.52.71.82
28.4184.956.147.240.3127.1211.8162.3138.290.850.643.61
0.20.50.40.50.51.11.113.82.91.910.77
0000000000000
0000000000000
0000000000000
0000000000000
0.3000.70.70.80.31.61.61.61.60.10.76
0.50.50.41.21.21.91.42.65.44.53.51.11.53
28.918.55.357.348.442.2128.5214.4167.7142.794.351.745.14
                         
000000000010010064.39
64.865.266.2125.2127.6154.3271.9406412.6437.6454.4462.5494.84
-56.3-52.7-63.3-74.4-87.2-119-152.3-200.6-258.4-309.5-372.9-419.6-456.49
0000000000000
0000000000000
8.512.52.950.840.435.3119.6205.4154.2128.181.64338.41
0.50.81.10.90.61.62.62.71.42.12.110.87
0.80.815.47.24.75.469.510.39.77.95.97
15.14.10.10.200.10.10.100000
0000000000000
0000000000000
16.45.72.26.57.86.48.18.810.912.411.88.96.84
0000000000000
0000000000000
40.20.100.20.80.70.62.82.20.900.07
40.20.100.20.80.70.62.82.20.900.07
20.45.92.36.587.28.89.413.714.612.78.96.9
28.918.45.257.348.442.5128.4214.8167.9142.794.351.945.32
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of GlycoMimetics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand GlycoMimetics's financial health and stability.

Assets

GlycoMimetics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that GlycoMimetics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of GlycoMimetics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into GlycoMimetics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
-63-10-11-12-31-33-48-57-51-63-46-36
0000000000000
0000000000000
19-14-552-100-13-1-4-2
0003457913141284
0000000000000
0000000000000
13-10-15-4-8-29-29-43-51-39-57-46-34
0000000000000
0000000000000
0000000000000
0000000000000
0000000000000
0005702311312901810428
0005702311312901810428
-------------
0000000000000
13-10-1552-8-68385-51-21-46-42-6
13.67-10.79-15.62-4.49-8.51-30.43-30.06-43.46-52.12-39.31-57.5-46.54-34.9
0000000000000

GlycoMimetics stock margins

The GlycoMimetics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of GlycoMimetics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for GlycoMimetics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the GlycoMimetics's sales revenue. A higher gross margin percentage indicates that the GlycoMimetics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the GlycoMimetics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the GlycoMimetics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the GlycoMimetics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the GlycoMimetics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the GlycoMimetics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

GlycoMimetics Margin History

GlycoMimetics Gross marginGlycoMimetics Profit marginGlycoMimetics EBIT marginGlycoMimetics Profit margin
2029e0 %0 %46.88 %
2028e0 %-178.54 %-28.27 %
2027e0 %-1,109.04 %-686.15 %
2026e0 %-3,462.87 %-2,596.17 %
2025e0 %-1,083.79 %-787.06 %
2024e0 %0 %0 %
20230 %-392,752.93 %-368,994.21 %
20220 %-59,250.01 %-58,362.5 %
20210 %-5,469.83 %-5,468.1 %
20200 %-506.99 %-502.26 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %-159,550 %-159,050 %
20150 %-63.68 %-63.63 %
20140 %-74.12 %-73.99 %
20130 %-265.91 %-265.91 %
20120 %23.85 %23.98 %
20110 %-159.58 %-160.37 %

GlycoMimetics Stock Sales Revenue, EBIT, Earnings per Share

The GlycoMimetics earnings per share therefore indicates how much revenue GlycoMimetics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue GlycoMimetics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates GlycoMimetics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of GlycoMimetics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating GlycoMimetics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

GlycoMimetics Revenue, EBIT and net profit per share

DateGlycoMimetics Sales per ShareGlycoMimetics EBIT per shareGlycoMimetics Earnings per Share
2029e1.2 undefined0 undefined0.56 undefined
2028e0.51 undefined0 undefined-0.14 undefined
2027e0.1 undefined0 undefined-0.69 undefined
2026e0.02 undefined0 undefined-0.52 undefined
2025e0.06 undefined0 undefined-0.44 undefined
2024e0 undefined0 undefined-0.62 undefined
20230 undefined-0.62 undefined-0.58 undefined
20220 undefined-0.9 undefined-0.89 undefined
20210.02 undefined-1.23 undefined-1.23 undefined
20200.22 undefined-1.13 undefined-1.12 undefined
20190 undefined-1.42 undefined-1.34 undefined
20180 undefined-1.25 undefined-1.18 undefined
20170 undefined-1.15 undefined-1.13 undefined
20160 undefined-1.5 undefined-1.5 undefined
20151.06 undefined-0.67 undefined-0.67 undefined
20140.81 undefined-0.6 undefined-0.6 undefined
20133.32 undefined-8.84 undefined-8.84 undefined
201212.72 undefined3.03 undefined3.05 undefined
20113.17 undefined-5.07 undefined-5.09 undefined

GlycoMimetics business model

GlycoMimetics Inc is a biopharmaceutical company specializing in the discovery and development of new drugs for the treatment of cancer and inflammatory diseases. The company was founded in 2003 and is headquartered in Rockville, Maryland. GlycoMimetics' business model is based on the application of glycomimetics, a class of molecules that mimic glycoproteins found in cells. These molecules act in various ways, offering unique therapeutic possibilities in the treatment of cancer and inflammatory diseases. The company conducts research and development in various areas, including the discovery of new drugs, preclinical and clinical drug development, and the evaluation of drug candidates for their transition into clinical trials. One of GlycoMimetics' most important developments is a drug called Rivipansel. This medication is used for the treatment of acute pain and crises in patients with sickle cell anemia. A Phase III clinical trial for Rivipansel was successfully completed in 2019. Another significant aspect of GlycoMimetics' business model is its collaboration with other companies specializing in similar technologies. For example, the company has partnered with Apollomics to advance the development of GMI-1271, a drug candidate for the treatment of Acute Myeloid Leukemia (AML). GlycoMimetics has various research and development areas that are crucial for the development and testing of drug candidates in clinical trials. The company has expertise in chemistry and biological sciences and employs researchers and scientists with diverse backgrounds. One of GlycoMimetics' divisions is medicinal chemistry, which focuses on the synthesis of natural compounds and chemical compounds to identify and develop new drug candidates. The company also has expertise in protein diagnostics, which are used to validate target molecules and assess the effectiveness of drug candidates. Another important division of GlycoMimetics is the field of immunology. Here, the company explores the role of glycoproteins in immune reactions and develops drugs for the treatment of autoimmune diseases. Overall, GlycoMimetics has strong research and development capabilities, enabling the company to develop new drug candidates, conduct clinical trials, and achieve successful growth. With its innovative developments and products, GlycoMimetics contributes to the improvement of the health of many patients and is an important player in the biopharmaceutical industry. GlycoMimetics is one of the most popular companies on Eulerpool.com.

GlycoMimetics SWOT Analysis

Strengths

GlycoMimetics Inc possesses several strengths that contribute to its competitiveness in the pharmaceutical industry. These strengths include:

  • Focused Research and Development: GlycoMimetics Inc maintains a strong focus on the research and development of novel glycomimetic drugs, enabling the company to stay at the forefront of this specialized field.
  • Valuable Intellectual Property: The company holds a robust portfolio of intellectual property rights, including patents and proprietary technologies, providing a competitive advantage in the market and protecting its innovations.
  • Strategic Partnerships: GlycoMimetics Inc has established strategic collaborations with reputable pharmaceutical companies, allowing for resource sharing, knowledge exchange, and potential co-development opportunities.
  • Strong Leadership Team: The company is led by a highly experienced management team with a track record of success in the pharmaceutical industry, providing effective guidance and decision-making.

Weaknesses

GlycoMimetics Inc also faces some weaknesses that could hamper its growth and performance. These weaknesses include:

  • Dependence on a Limited Product Portfolio: As a specialized pharmaceutical company, GlycoMimetics Inc relies heavily on the success of a limited number of drug candidates, increasing the vulnerability to failure in clinical trials or market acceptance.
  • Financial Constraints: Like many emerging biotech companies, GlycoMimetics Inc faces financial challenges, including limited financial resources and potential difficulties in securing additional funding for research and development activities.
  • Limited Market Presence: Compared to larger pharmaceutical companies, GlycoMimetics Inc has a relatively small market presence, which may pose challenges in terms of market penetration, distribution, and brand recognition.

Opportunities

Despite the challenges, there are several opportunities available to GlycoMimetics Inc that can support its growth and expansion. These opportunities include:

  • Expanding Therapeutic Applications: GlycoMimetics Inc can explore potential applications of its glycomimetic technology beyond its current focus areas, diversifying its product pipeline and reaching new patient populations.
  • Regulatory Advancements: Advances in regulatory pathways for novel therapies, such as expedited approval programs, can provide opportunities for GlycoMimetics Inc to accelerate the development and commercialization of its drug candidates.
  • Global Partnerships and Market Expansion: The company can seek partnerships with international pharmaceutical companies to expand its geographic presence, access new markets, and benefit from regional expertise and resources.

Threats

GlycoMimetics Inc faces several threats in the competitive landscape of the pharmaceutical industry. These threats include:

  • Intense Industry Competition: The pharmaceutical industry is highly competitive, with numerous large and small companies vying for market share. This competitive landscape poses challenges in terms of gaining market acceptance and differentiating its products.
  • Uncertain Regulatory Environment: Changes in regulatory requirements or delays in regulatory approvals can negatively impact the timelines and costs associated with the development and commercialization of GlycoMimetics Inc's drug candidates.
  • Technological Advancements: The rapid pace of technological advancements in the pharmaceutical industry can pose threats. If GlycoMimetics Inc fails to keep up with emerging technologies or competitors' innovations, it may struggle to maintain a competitive edge.

GlycoMimetics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

GlycoMimetics historical P/E ratio, EBIT multiple, and P/S ratio

GlycoMimetics shares outstanding

The number of shares was GlycoMimetics in 2023 — This indicates how many shares 63.342 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue GlycoMimetics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates GlycoMimetics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of GlycoMimetics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating GlycoMimetics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for GlycoMimetics.

GlycoMimetics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.17 -0.16  (6.38 %)2024 Q2
3/31/2024-0.17 -0.17  (-1.01 %)2024 Q1
12/31/2023-0.16 -0.14  (10.03 %)2023 Q4
9/30/2023-0.15 -0.14  (4.24 %)2023 Q3
6/30/2023-0.19 -0.13  (30.48 %)2023 Q2
3/31/2023-0.17 -0.17  (0 %)2023 Q1
12/31/2022-0.17 -0.19  (-11.76 %)2022 Q4
9/30/2022-0.27 -0.16  (40.43 %)2022 Q3
6/30/2022-0.29 -0.25  (14 %)2022 Q2
3/31/2022-0.31 -0.28  (10.49 %)2022 Q1
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the GlycoMimetics stock

Eulerpool World ESG Rating (EESG©)

32/ 100

🌱 Environment

19

👫 Social

41

🏛️ Governance

35

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety❌
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

GlycoMimetics shareholders

%
Name
Stocks
Change
Date
6.21585 % New Enterprise Associates (NEA)4,007,977-756,4632/28/2024
4.65261 % Octagon Capital Advisors LP3,000,000012/31/2023
3.75600 % The Vanguard Group, Inc.2,421,869012/31/2023
2.46169 % AXA Investment Managers UK Ltd.1,587,298-38,40012/31/2023
14.80190 % BVF Partners L.P.9,544,262012/31/2023
13.32051 % Invus Public Equities Advisors, LLC8,589,064012/31/2023
1.42580 % Goldman Sachs & Company, Inc.919,355124,86112/31/2023
1.11403 % BlackRock Institutional Trust Company, N.A.718,3291,57712/31/2023
0.98485 % King (Rachel K)635,03325,6563/29/2024
0.83929 % Acadian Asset Management LLC541,176-302,87512/31/2023
1
2
3
4
5
...
10

GlycoMimetics Executives and Management Board

Mr. Harout Semerjian52
GlycoMimetics President, Chief Executive Officer, Director (since 2021)
Compensation 1.43 M
Mr. Brian Hahn48
GlycoMimetics Chief Financial Officer, Senior Vice President - Finance
Compensation 918,191
Ms. Rachel King63
GlycoMimetics Co-Founder, Director (since 2003)
Compensation 235,673
Mr. Timothy Pearson55
GlycoMimetics Independent Chairman of the Board
Compensation 91,240
Mr. Daniel Junius70
GlycoMimetics Independent Director
Compensation 71,740
1
2
3

Most common questions regarding GlycoMimetics

What values and corporate philosophy does GlycoMimetics represent?

GlycoMimetics Inc represents a strong commitment to scientific innovation and improving patient outcomes. The company's core values include integrity, collaboration, and scientific excellence. With a focus on developing novel glycomimetic therapeutics, GlycoMimetics strives to address unmet medical needs in areas such as oncology and hematology. By leveraging their expertise in carbohydrate chemistry, GlycoMimetics aims to deliver breakthrough treatments that have the potential to positively impact patients' lives. Through a culture of innovation and a dedication to integrity, GlycoMimetics is driven by a corporate philosophy centered on advancing science and enriching the healthcare landscape.

In which countries and regions is GlycoMimetics primarily present?

GlycoMimetics Inc is primarily present in the United States.

What significant milestones has the company GlycoMimetics achieved?

GlycoMimetics Inc has achieved several significant milestones. The company successfully developed and advanced multiple product candidates, including their lead candidate, rivipansel, which is being developed for the treatment of vaso-occlusive crisis associated with sickle cell disease. GlycoMimetics Inc also entered into a collaboration with Pfizer Inc, a global pharmaceutical company, to develop and commercialize rivipansel. Additionally, the company successfully completed a Phase 3 clinical trial for rivipansel, demonstrating its potential efficacy and safety. These achievements highlight GlycoMimetics Inc's dedication to developing innovative therapies and forging valuable partnerships in the pharmaceutical industry.

What is the history and background of the company GlycoMimetics?

GlycoMimetics Inc is a pharmaceutical company specializing in the discovery and development of novel glycobiology-based therapies. Founded in 2003, GlycoMimetics focuses on developing drugs that inhibit selectin molecules to treat diseases such as sickle cell disease, acute myeloid leukemia, and other inflammatory conditions. The company's proprietary drug candidates have shown promising results in clinical trials, demonstrating their potential to address unmet medical needs. With a strong commitment to innovation and scientific excellence, GlycoMimetics continues to advance its pipeline and collaborate with industry leaders to bring transformative treatments to patients worldwide.

Who are the main competitors of GlycoMimetics in the market?

The main competitors of GlycoMimetics Inc in the market include companies such as Pfizer, Inc., Eli Lilly and Company, and Novartis AG.

In which industries is GlycoMimetics primarily active?

GlycoMimetics Inc is primarily active in the biotechnology industry.

What is the business model of GlycoMimetics?

The business model of GlycoMimetics Inc focuses on the development and commercialization of therapeutics for patients with unmet medical needs. The company is dedicated to creating innovative, targeted therapies that address specific diseases and conditions. GlycoMimetics Inc leverages its expertise in glycobiology to design and develop novel small molecules that mimic the natural biological processes in the body. By targeting glycans, essential components of cellular interactions, the company aims to develop breakthrough treatments for various diseases, including hematologic malignancies and sickle cell disease. With a focus on research and strategic partnerships, GlycoMimetics Inc strives to bring transformative therapies to patients worldwide.

What is the P/E ratio of GlycoMimetics 2024?

The GlycoMimetics P/E ratio is -0.26.

What is the P/S ratio of GlycoMimetics 2024?

The GlycoMimetics P/S ratio is 0.

What is the AlleAktien quality score of GlycoMimetics?

The AlleAktien quality score for GlycoMimetics is 3/10.

What is the revenue of GlycoMimetics 2024?

The revenue cannot currently be calculated for GlycoMimetics.

How high is the profit of GlycoMimetics 2024?

The expected GlycoMimetics profit is -39.96 M USD.

What is the business model of GlycoMimetics

GlycoMimetics Inc is a biotechnology company based in the USA. The company's business model is based on the development and commercialization of novel therapeutic agents that are based on the imitation of carbohydrate structures in cells and tissues. These substances, called GlycoMimetics, can be used to treat a variety of diseases, particularly those related to disorders of the circulatory system, inflammatory processes, or cancer growth. The company is divided into two main areas: research and development (R&D) and production and marketing (Sales & Marketing), with activities focusing on both internal and external collaboration. In the R&D area, intensive research is being conducted to identify new GlycoMimetics, with the company working closely with academic institutions and other biotechnology companies to maximize the full potential of its research results. A focus of GlycoMimetics Inc is the research and development of drugs for the treatment of cancer. Novel Glycomimetics are being targeted as targets for the development of cancer therapeutics. The company's current developments focus on drug candidates for the therapy of acute myeloid leukemia (AML), non-Hodgkin lymphoma, and colon cancer. In addition, new treatment approaches to improve blood formation and blood clotting are also being developed. These approaches have the potential to reduce the need for blood transfusions or improve the tolerability of other medications. Another future business field of GlycoMimetics Inc is the targeted addressing of inflammatory processes. GlycoMimetics have the ability to selectively target inflammatory cells and leave healthy cells unaffected without side effects or damage. This is used in the development of treatment options for inflammatory diseases such as rheumatoid arthritis, multiple sclerosis (MS), psoriasis, and autoimmune diseases such as type I diabetes. GlycoMimetics Inc offers its products directly to medical institutions as well as in cooperation with leading pharmaceutical companies. International partnerships are already being formed to globally market the effectiveness of GlycoMimetics on the world market. As a result, GlycoMimetics secures numerous partnerships to profitably sell its expertise and developments. Overall, the business model of GlycoMimetics Inc is focused on the identification and commercialization of innovative and effective GlycoMimetics. The application spectrum and potential of GlycoMimetics are wide-ranging, supporting the company's growth and expansion strategy. GlycoMimetics will revolutionize the treatment of numerous patients and usher in a new era in medicine.

What is the GlycoMimetics dividend?

GlycoMimetics pays a dividend of 0 USD distributed over payouts per year.

How often does GlycoMimetics pay dividends?

The dividend cannot currently be calculated for GlycoMimetics or the company does not pay out a dividend.

What is the GlycoMimetics ISIN?

The ISIN of GlycoMimetics is US38000Q1022.

What is the GlycoMimetics WKN?

The WKN of GlycoMimetics is A1W8HZ.

What is the GlycoMimetics ticker?

The ticker of GlycoMimetics is GLYC.

How much dividend does GlycoMimetics pay?

Over the past 12 months, GlycoMimetics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, GlycoMimetics is expected to pay a dividend of 0 USD.

What is the dividend yield of GlycoMimetics?

The current dividend yield of GlycoMimetics is .

When does GlycoMimetics pay dividends?

GlycoMimetics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of GlycoMimetics?

GlycoMimetics paid dividends every year for the past 0 years.

What is the dividend of GlycoMimetics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is GlycoMimetics located?

GlycoMimetics is assigned to the 'Health' sector.

Wann musste ich die Aktien von GlycoMimetics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of GlycoMimetics from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did GlycoMimetics pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of GlycoMimetics in the year 2023?

In the year 2023, GlycoMimetics distributed 0 USD as dividends.

In which currency does GlycoMimetics pay out the dividend?

The dividends of GlycoMimetics are distributed in USD.

All fundamentals about GlycoMimetics

Our stock analysis for GlycoMimetics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of GlycoMimetics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.